Johnson & Johnson announces offer to acquire Ci:z Holdings Co

Ci:z Holdings Co owns the Dr.Ci:Labo, Labo Labo and Genomer brands

US-based conglomerate Johnson & Johnson (J&J) has made an offer to buy Japanese cosmetics maker Ci:z Holdings Co in a move to strengthen its presence in Japan and bolster its roster of dermocosmetics brands.

Johnson & Johnson is to buy all the outstanding shares in Ci:z Holdings Co that it does not already own for around ¥230bn ($2.05bn)—or ¥5,900 ($52.6) per share—in cash.

Ci:z Holdings Co markets, develops and distributes a range of dermocosmetic, cosmetic and skincare products under the Dr.Ci:Labo, Labo Labo and Genomer brands.

Beyond strengthening its presence in Japan and adding to its skincare portfolio, the deal also gives J&J access to what it says is one of the largest CRM databases for direct-to-consumer skincare in Japan. J&J also plans to develop Ci:z Holdings’ portfolio and its distribution.

In July 2016, J&J affiliate Cilag forged a long-term partnership with Ci:z Holdings Co to distribute the company’s brands outside Japan. Cilag acquired around 19.9% of the company’s outstanding shares as part of the deal.

J&J plans to launch the tender offer on October 29, 2018. It is expected to close in the first quarter of 2019. Following this, J&J is planning a squeeze-out procedure to purchase the remaining shares in the company that were not tendered in the tender offer, which is expected to be complete in the first half of 2019.

82790b6a8da637e56ddebab62389eb22MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM